Why the study?
Genetic testing for HCM cascade screening exempts genotype-negative relatives from lifelong surveillance but remains unavailable in Brazil's public health system.
Does genetic testing improve cost-utility compared to clinical screening in relatives of patients with hypertrophic cardiomyopathy?
Does genetic testing improve cost-utility compared to clinical screening in relatives of patients with hypertrophic cardiomyopathy?
Genetic testing is a cost-effective strategy for HCM cascade screening in Brazil's public health system, optimizing resource allocation by exempting genotype-negative relatives from lifelong surveillance.
Answers are grounded in this paper and cite their sources.
Supports incorporating genetic testing into HCM family screening in Brazil's SUS; extends cost-utility evidence to public systems in middle-income countries.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant myocardial disorder affecting 0·2% of the global population and a leading cause of sudden cardiac death in young individuals and athletes. Current guidelines recommend periodic clinical screening of first-degree relatives for early diagnosis and risk stratification. Genetic testing identifies at-risk individuals while exempting genotype-negative relatives from lifelong surveillance. However, it remains unavailable in Brazil's public health system (Sistema Único de Saúde, SUS). This study aimed to evaluate the cost-utility of genetic testing for HCM cascade screening in Brazil. METHODS: A cost-utility analysis was conducted from the SUS perspective, using a hybrid decision tree and Markov model to project lifetime costs and health outcomes. Inputs were derived from literature and validated by a multidisciplinary expert panel. Genetic testing costs were micro-costed; other costs were obtained from Brazil's national reimbursement database (SIGTAP). Effectiveness was measured in quality-adjusted life-years (QALYs). Deterministic and probabilistic analyses assessed model robustness. FINDINGS: Genetic testing was cost-effective (incremental cost-effectiveness ratio: US$1411 per QALY), yielding an incremental gain of 0·06 QALYs per relative at an additional cost of $87 per relative. Utility values had the greatest influence on cost-utility outcomes. In probabilistic analysis, genetic testing was cost-effective in 99·4% of simulations at the Brazilian willingness-to-pay threshold of $7421 per QALY. In the base-case hypothetical cohort of 1000 relatives (250 probands with four first-degree relatives each), 205 (20·5%) of 1000 relatives were exempted from lifelong surveillance, reducing screening visits by 18·6% per tested individual. INTERPRETATION: Genetic testing is a cost-effective strategy for HCM cascade screening in Brazil's public health system. By exempting genotype-negative relatives from lifelong surveillance, it optimises resource allocation, reduces unnecessary follow-ups and psychological burden, and supports informed family planning. These findings provide an economic evidence base for integrating genetic testing into SUS clinical practice guidelines.
No takes yet. Share an insight, caveat, or question.
Braga et al. (2026) studied Hypertrophic cardiomyopathy (n=1,000). Genetic testing vs. Clinical screening was evaluated on Incremental cost-effectiveness ratio (ICER) in US$ per QALY (ICER US$1411 per QALY). Genetic testing for hypertrophic cardiomyopathy cascade screening was cost-effective compared to clinical screening, with an incremental cost-effectiveness ratio of US$1411 per QALY.
Synapse has enriched 10 related papers. Consider them for comparative context: